TABLE 3.
Patient details of surgery and postoperative information in the targeted therapy plus SS group
| Case | Mode of surgery | Postoperative CS | Adjuvant therapy | Final outcome |
|---|---|---|---|---|
| 1 | VATS lobectomy + SML | pT2N0M0R0,IB | Gefitinib (13 months) | Progression of Pubic bone metastasis |
| 2 | VATS lobectomy + SML | pT2N2M0R0,IIIA | Gefitinib (6 months) | Progression of intrapulmonary metastasis |
| 3 | VATS lobectomy + SML | pT1bN0M0R0,IA | Gefitinib (13 months) | Progression of Pubic bone metastasis |
| 4 | VATS lobectomy + SML | pT1N2M0R0,IIIA | Gefitinib (12 months) | Progression‐free |
| 5 | VATS lobectomy + SML | pT1N0M0R0,IA | Gefitinib (17 months) | Progression‐free |
| 6 | VATS lobectomy + SML | pT1N0M0R0,IA | Gefitinib (17 months) | Progression of intrapulmonary metastasis |
| 7 | VATS lobectomy + SML | pT1bN0M0R0,IA | Gefitinib (10 months) | Progression of supraclavicular lymph nodes |
| 8 | VATS lobectomy + SML | pCR | Crizotinib (12 months) | Progression of intracranial metastasis |
| 9 | VATS lobectomy + SML | pT1cN0M0R0,IA | Gefitinib (29 months) | Progression of brain metastasis |
| 10 | VATS lobectomy + SML | pT1bN0M0R0,IA | Gefitinib (27 months) | Progression‐free |
| 11 | VATS lobectomy + SML | pT1bN0M0R0,IA | Gefitinib (25 months) | Progression‐free |
| 12 | VATS lobectomy + SML | pT1aN0M0R0,IA | Crizotinib (24 months) | Progression‐free |
| 13 | VATS lobectomy + SML | pT1bN0M0R0,IA(MPR) | Gefitinib (24 months) | Progression‐free |
| 14 | VATS lobectomy + SML | pT1aN2M0R0,IIIA | Gefitinib (14 months) | Progression‐free |
| 15 | VATS lobectomy + SML | pT1bN0M0R0,IA | Gefitinib (28 months) | Progression‐free |
| 16 | VATS lobectomy + SML | pCR | Gefitinib (8.5 months) | Progression of bone metastasis |
| 17 | Sleeve lobectomy + SML | pT2N2M0R0,IIIA | Gefitinib (4 months) | Progression of intrapulmonary metastasis |
| 18 | VATS lobectomy + SML | pT1aN0M0R0,IA(MPR) | Gefitinib (3 months) | Progression‐free |
Abbreviations: MPR, major pathological response; pCR, pathological complete response; SML, systematic mediastinal lymphadenectomy; VATS, video‐assisted thoracoscopic surgery.